Dual diagnosis treatment for Miami — one team, both diagnoses, together.

RECO Health treats co-occurring substance use disorder and psychiatric illness on the same treatment plan, by the same clinical team — not as sequential problems. For clients driving 65 minutes from Brickell, Coral Gables, or Aventura, that means one in-house psychiatrist managing both MAT (buprenorphine, naltrexone) and psychotropic medication, dually credentialed therapists running CBT, DBT, and EMDR, and access to in-house rTMS and ketamine for treatment-resistant presentations. The geographic distance from Miami's social triggers is a clinical feature, not a logistical obstacle.

For clients in Brickell, Coral Gables, Coconut Grove, Aventura, and Pinecrest, RECO Health’s Delray Beach campus sits roughly 50 miles north — a 65-minute drive up I-95 outside rush hour. Most Miami admissions to dual diagnosis treatment pair clinical care with on-site sober living rather than a daily commute, because the geographic distance from Miami’s nightlife, dealer networks, and long-standing social triggers is part of the clinical value, not a scheduling inconvenience. Co-occurring substance use and psychiatric illness require an integrated treatment model, and integration is what defines the RECO program.

Why sequential treatment fails for co-occurring disorders

The research on co-occurring disorders has been unambiguous for two decades: sequential treatment — the “get sober first, then we’ll address the mental health” model — produces measurably worse outcomes than integrated treatment. Untreated depression during early recovery drives anhedonia, cognitive distortions, and craving intensity that predict relapse within the first 90 days. Untreated substance use during a course of SSRIs blunts antidepressant response, in part because active alcohol or stimulant use disrupts the same neurotransmitter systems the medication is trying to stabilize.

Integrated treatment — one team, one plan, both diagnoses addressed concurrently — is the standard of care described in SAMHSA’s TIP 42 and endorsed by APA and ASAM. It requires clinicians credentialed in both addiction medicine and psychiatric care, which is rarer in practice than in advertising. At RECO Health, therapists carry dual credentials in substance use counseling and mental health disciplines, and the psychiatric team practices addiction psychiatry directly rather than referring out to a community provider whose caseload the program cannot see.

The high-prevalence co-occurring diagnoses

Five diagnoses account for the majority of dual diagnosis presentations: major depressive disorder, PTSD, generalized anxiety disorder, bipolar disorder, and ADHD. RECO screens all five at intake using validated instruments — the PHQ-9 for depression, PCL-5 for PTSD, GAD-7 for anxiety, MDQ for bipolar screening, and ASRS for ADHD. A positive screen triggers a full diagnostic interview with the psychiatric team within 72 hours, not weeks later.

Each diagnosis has a defined evidence-based pathway inside the program. Depression is treated with SSRIs like sertraline or escitalopram, or SNRIs, paired with CBT and behavioral activation. PTSD moves through cognitive processing therapy, prolonged exposure, or EMDR once stabilization allows. Bipolar disorder involves mood stabilizer optimization — lithium, lamotrigine, or an atypical antipsychotic such as quetiapine, olanzapine, or aripiprazole — with adherence support built into the milieu. ADHD is approached with non-stimulant options first, or a carefully monitored stimulant with clear contingencies when clinically indicated. OCD presentations are screened with the YBOCS and treated with SSRIs plus exposure and response prevention.

MAT and psychotropic medication managed by one psychiatrist

Buprenorphine or naltrexone for opioid use disorder, naltrexone or acamprosate for alcohol use disorder, and the client’s antidepressant, mood stabilizer, or ADHD medication are all managed by the same in-house psychiatrist. Drug-drug interactions are addressed upfront — the QT-prolonging combination of methadone and certain antipsychotics, the sedation risk of benzodiazepines layered on buprenorphine, the reduced seizure threshold of bupropion in an actively drinking client. These are not abstract concerns; they cause hospitalizations and, in some cases, deaths.

Fragmented prescribing — a primary care doctor writing the antidepressant, an outside psychiatrist writing the mood stabilizer, and a separate MAT clinic writing buprenorphine — is among the most common relapse pathways in dual diagnosis care. No one prescriber owns the full picture, and adherence data lives in three separate charts that never talk to each other. RECO’s integrated model closes that gap by design, with a single psychiatric chart and a single treatment plan. For alcohol use disorder, naltrexone (oral or long-acting injectable Vivitrol) reduces craving intensity while acamprosate stabilizes glutamatergic tone in early sobriety; the choice is guided by liver function, adherence history, and prior response.

Trauma is often the through-line

For a substantial share of dual diagnosis clients, unprocessed trauma is upstream of both the substance use and the mood disorder. The substance use often began as functional self-medication for hyperarousal, intrusive memories, or emotional numbing, and treating the addiction while leaving the trauma untouched typically holds for six to nine months and then fails, often catastrophically. That failure pattern is the reason RECO treats trauma as a first-tier diagnosis whenever the PCL-5 or clinical interview flags it, rather than deferring it to aftercare.

RECO’s protocol screens for trauma at intake with the PCL-5 and a structured trauma history, stabilizes symptoms early using DBT skills, ACT-based defusion work, and grounding techniques, and moves into evidence-based trauma processing — CPT, prolonged exposure, or EMDR — once the client’s window of tolerance supports it. For treatment-resistant depression or PTSD that has not responded to standard care, RECO offers in-house ketamine and rTMS. Transcranial magnetic stimulation is delivered on the standard FDA protocol: 3,000 pulses per session at 120% of motor threshold, five days a week for approximately six weeks, with concurrent psychotherapy.

What to expect on the first visit from Miami

Admissions for Miami clients typically begin with a phone assessment while the client is still in Brickell, Coral Gables, or wherever they are currently living, followed by a scheduled arrival at the Delray Beach campus. Day one includes vitals, urine toxicology, a CIWA-Ar for alcohol withdrawal risk or COWS for opioid withdrawal, a full medication reconciliation, and psychiatric evaluation. ASAM Criteria dimensions guide the initial level-of-care decision — detox, residential, PHP, IOP, or outpatient — and the assignment is revisited weekly against clinical progress.

For clients arriving from Miami with active alcohol, benzodiazepine, or opioid dependence, medically supervised detox is often the first phase. Alcohol and benzodiazepine withdrawal carry seizure and delirium risk and are managed with tapered benzodiazepine protocols and serial CIWA-Ar monitoring. Opioid withdrawal is rarely medically dangerous but is severe enough to derail treatment; RECO manages it with buprenorphine induction or non-opioid comfort medications depending on the client’s MAT plan and preferences established through motivational interviewing.

Insurance, admissions, and getting to Delray Beach from Miami

RECO Health works with most major commercial insurers, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans. The admissions team runs a full verification of benefits before admission and provides a written estimate that itemizes deductible, coinsurance, and any out-of-pocket for adjunctive services such as TMS or ketamine if they are part of the treatment plan. Level of care — detox, residential, PHP, or IOP — drives the coverage picture more than any other variable, and the estimate is completed against a specific placement rather than a generic quote.

The drive from Miami to the Delray Beach campus is 50 miles up I-95, typically 65 minutes outside rush hour. For clients entering residential care or PHP with on-site housing, transportation from Miami-Dade can be arranged. For IOP or outpatient tracks the drive is manageable, but most Miami clients ultimately choose the housed track — the geographic and social distance from Wynwood, South Beach, and Brickell nightlife is often the difference between a sustainable recovery and a repeat admission six months later.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.